The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
A family-based analysis led to an X chromosome variant in MAGEC3 that appeared to contribute to early-onset ovarian cancer risk in sisters and their paternal grandmothers.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
LSU Health New Orleans and OmniSeq will collaborate to offer next-generation sequencing-based tumor profiling services to the institution's oncologists.
OmniSeq's goal is to make cancer genomic testing available to institutions, including comprehensive cancer centers, oncology practices, and community oncology groups.
NEW YORK (GenomeWeb) – Roswell Park Cancer Institute today said that the New York State Department of Health has granted approval for the institute to test cancer patients using its OmniSeq Target molecular diagnostic test.
